
Opinion|Videos|December 16, 2024
Managing CRS and ICANS: Approaches and Protocols
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how clinical management of CAR T-cell therapy–associated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms.
Advertisement
Episodes in this series

Video content above is prompted by the following
What is your approach to managing toxicities such as CRS and ICANS?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
2
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
3
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review
4
January 2026 Product Updates
5




















